Medi-Mibi

Technetium-99m sestamibi, the active ingredient in Medi-Mibi, is a radiopharmaceutical presented as an injectable solution for intravenous use. It is employed in diagnostic imaging to assess myocardial perfusion, detect coronary artery disease, and locate abnormal parathyroid tissue in adult patients.

GNH USA supplies Medi-Mibi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide, providing regulated distribution to healthcare facilities and ensuring quality and compliance across global markets.

Medi-Mibi is used in nuclear medicine to evaluate cardiac and parathyroid conditions through perfusion imaging.

- Myocardial perfusion imaging (stress and rest): enables visualization of regional blood flow and identification of perfusion defects. - Coronary artery disease detection: assists clinicians in locating ischemic myocardial regions for diagnostic assessment. - Parathyroid imaging: helps locate hyperfunctioning parathyroid glands prior to surgical intervention.

Adverse reactions to Medi-Mibi are generally related to the radiopharmaceutical nature of the product and the injection process.

Common Side Effects: - Injection site pain: mild discomfort at the venipuncture site. - Nausea: transient feeling of queasiness following administration. - Headache: mild to moderate headache occurring shortly after injection. - Flushing or warmth: brief sensation of warmth or skin flushing.

Serious or Rare Side Effects: - Allergic reaction: rash, itching, or hives indicating hypersensitivity. - Anaphylaxis: severe, potentially life‑threatening systemic reaction requiring immediate medical attention. - Radiation‑induced skin injury: localized erythema or ulceration at high exposure sites.

When using Medi-Mibi, several precautions should be observed to ensure patient safety and optimal imaging results.

- Patient preparation: ensure adequate hydration before and after injection to facilitate tracer clearance. - Contraindications: avoid use in individuals with known hypersensitivity to technetium‑99m sestamibi. - Pregnancy: do not administer unless the diagnostic benefit outweighs potential fetal radiation risk. - Radiation safety: follow ALARA principles and protect staff and family from unnecessary exposure. - Monitoring: observe patients during and after injection for any immediate adverse reactions. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake the vial.

Medi-Mibi may interact with other agents that influence myocardial blood flow or cumulative radiation exposure.

Major Interactions (Avoid): - Concurrent radiopharmaceuticals: avoid administering other radioactive tracers within a short interval to prevent excessive radiation dose.

Moderate Interactions (Monitor Closely): - Beta‑blockers, calcium channel blockers, nitrates: these cardiovascular drugs can alter myocardial perfusion and affect imaging interpretation. - Thyroid hormone therapy: may modify tracer distribution in thyroid tissue. - Iodinated contrast agents: recent use can interfere with subsequent nuclear imaging studies. - Chemotherapeutic agents: some may impact organ function and tracer kinetics.